Should I Buy AMRZ? AMRZ 2026 Analysis

Should You Buy Amrize AG (AMRZ) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

58.410

1 Day change

5.05%

52 Week Range

58.470

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action/indicators are neutral-to-soft (negative MACD, no momentum edge) and pattern-based stats point to near-term downside.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Options positioning is call-skewed (bullish), but it’s not strong enough to override weakening technicals and the short-term downside probability.
With earnings coming 2026-02-17 (After Hours), there’s event risk without a clear technical setup; for an impatient buyer, this is an avoid-now / don’t chase setup.

Technical Analysis

Trend/Momentum: MACD histogram -0.223 (below 0) and only negatively contracting → downside bias persists, not a clean reversal.
RSI (6): 51.2 (neutral) → no oversold bounce signal.
Moving averages: converging → consolidation/indecision rather than a strong uptrend.
Levels to watch: Pivot 53.879 (current ~53.7 slightly below pivot = weak). Resistance 55.03 / 55.74; Support 52.73 / 52.02.
Quant/pattern read-through: similar-pattern outcome suggests 70% chance of -2.97% next day, -7.4% next week, -5.2% next month → near-term odds favor downside.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/Call ratios (OI 0.41, Volume 0.45) imply bullish/call-heavy positioning.
Positioning detail: Call OI 18,782 vs Put OI 7,675 → call skew.
Volatility: IV30 31.2 vs Hist Vol 28.63 (modest premium); IV Rank 3.64 / IV Percentile 28.57 → volatility relatively low vs its history (options not “expensive”).
Activity: Today’s options volume 61 (calls 42, puts 19).

Technical Summary

Sell

Buy

Positive Catalysts

- Street narrative remains constructive around infrastructure exposure and potential housing/remodeling recovery (per Wells Fargo/Citi commentary).
- Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-17 (AH) could re-rate shares if margins/volumes surprise positively.
- Options market shows call-skewed sentiment (low put/call ratios).

Neutral/Negative Catalysts

- Technical bias is weak: price slightly below pivot with negative MACD and no buy signals from Intellectia modules.
- Short-term probability skew (pattern-based) points to higher odds of declines over 1D/1W/1M.
- Analyst caution exists on fundamentals: outlook for U.S. cement volumes “remains subdued” (RBC commentary).
- No supportive news flow in the last week to act as an upside catalyst.

Financial Performance

Latest quarter: 2025/Q3
Revenue $3.675B, +6.65% YoY (top-line growth positive).
Profitability slightly weaker: Net Income $545M, -1.45% YoY; EPS 0.98, -2.00% YoY.
Margins: Gross Margin 29.55%, down ~2.28% YoY → growth is not translating cleanly into higher earnings.
Ownership/trading: Hedge funds neutral (no notable last-quarter trend); insiders neutral (no notable last-month trend).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst actions show a generally bullish bias with mixed conviction:
- Wells Fargo (2026-01-29): Overweight; PT $59 (raised from $58).
- Citi (2026-01-08): Buy; PT $67 (raised from $63).
- Deutsche Bank (2025-12-08): Buy; PT $59 (cut from $62).
- RBC (2025-12-08): Downgraded to Sector Perform; PT $60 (raised from $56); cites subdued U.S. cement volumes.
- Vertical Research (2025-11-25): Initiated Hold; PT $54.
- Stephens (2025-11-14): Initiated Overweight; PT $60.
Wall St pros: infrastructure/heavy materials positioning; potential cyclical recovery tailwinds.
Wall St cons: volume/margin skepticism near-term; outperformance may require execution (“self-help”) and/or improved demand.
Influential/political trading: No recent congress trading data available (last 90 days).

15 Analyst Rating

Wall Street analysts forecast AMRZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRZ is 59.94 USD with a low forecast of 52.44 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

5 Hold

0 Sell

Moderate Buy

Current: 55.600

Low

52.44

Averages

59.94

High

Current: 55.600

Low

52.44

Averages

59.94

High

Wells Fargo

Overweight

maintain

$58 -> $59

AI Analysis

2026-01-29

Reason

Wells Fargo

Price Target

$58 -> $59

AI Analysis

2026-01-29

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Amrize to $59 from $58 and keeps an Overweight rating on the shares. The firm remains selective in its building mats recommendations, preferring early-cycle exposure as Wells anticipates some housing/remodeling recovery.

Citi

Buy

upgrade

$63 -> $67

2026-01-08

Reason

Citi

Price Target

$63 -> $67

2026-01-08

upgrade

Buy

Reason

Citi raised the firm's price target on Amrize to $67 from $63 and keeps a Buy rating on the shares. The firm updated estimates and targets in the homebuilding and building products group as part of its 2026 outlook. Citi continues to prefer heavy construction materials with exposure to infrastructure over the residential exposed names.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AMRZ

Unlock Now

AMRZ Should I Buy

AMRZ Should I Buy

Should You Buy Amrize AG (AMRZ) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch